Vitamin C and the common cold: a retrospective analysis of Chalmers’ review. by Hemilä, Harri & Herman, Zelek S
Vitamin C and the Common Cold: A Retrospective Analysis of Chalmers' Review
Harri Hemilä and Zelek S. Herman
From the Department of Public Health, University of Helsinki, Finland; and 
Linus Pauling Institute of Science and Medicine, Palo Alto, California
Journal of the American College of Nutrition 1995;14:116-123.
Published version is available at: http://dx.doi.org/10.1080/07315724.1995.10718483 
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/7790685 
This is a manuscript version of the 1995 publication with links added to the references
Harri Hemilä
harri.hemila@helsinki.fi 
http://www.mv.helsinki.fi/home/hemila  
http://www.mv.helsinki.fi/home/hemila/vitc_colds.htm (papers on vit C and colds)
The Chalmers 1975 review has been highly influential as a support to statements 
that vitamin C does not have any effects on the common cold. 
See a list of influential monographs and journal articles that have cited 
the Chalmers 1975 review as evidence that vitamin C is useless for colds:
http://www.mv.helsinki.fi/home/hemila/  Chalmers1975CitedBy  .htm   
Problems in influential reviews on vitamin C and the common cold are discussed also in:
Hemilä H. 
Vitamin C supplementation and common cold symptoms: problems with inaccurate reviews.
Nutrition 1996;12:804-809
http://dx.doi.org/10.1016/S0899-9007(96)00223-7  
http://hdl.handle.net/10250/7979  Manuscript version with links to references added.
In his review, Chalmers put a great weight on the Karlowski (1975) study. 
However, the Karlowski study was shown to be erroneously analysed in 1996:
Hemilä H. 
Vitamin C, the placebo effect, and the common cold: 
a case study of how preconceptions influence the analysis of results. 
J Clin Epidemiol 1996;49:1079-1084
http://dx.doi.org/10.1016/0895-4356(96)00189-8  
http://hdl.handle.net/10250/8082  Manuscript version with links to references added.
For further discussions on the problems with the influential reviews and the Karlowski study, see:
Hemilä H. Do vitamins C and E affect respiratory infections? Thesis 2006 pp. 21-7, 35-45.
http://hdl.handle.net/10138/20335  
Relevant sections are also available as html files:
http://www.mv.helsinki.fi/home/hemila/reviews     (problems with the influential reviews)
http://www.mv.helsinki.fi/home/hemila/karlowski  (problems with the Karlowski 1975 study)
1
Vitamin C and the Common Cold: A Retrospective Analysis of Chalmers' Review
Harri Hemilä and Zelek S. Herman
Journal of the American College of Nutrition 1995;14:116-123.
Published version: http://dx.doi.org/10.1080/07315724.1995.10718483 
PubMed: http://www.ncbi.nlm.nih.gov/pubmed/7790685 
Abstract
In 1975 Thomas Chalmers analyzed the possible effect of vitamin C on the common cold 
by calculating the average difference in the duration of cold episodes in vitamin C and control 
groups in seven placebo-controlled studies. He found that episodes were 0.11 ± 0.24 (SE) days 
shorter in the vitamin C groups and concluded that there was no valid evidence to indicate that 
vitamin C is beneficial in the treatment of the common cold. Chalmers' review has been 
extensively cited in scientific articles and monographs. However, other reviewers have 
concluded that vitamin C significantly alleviates the symptoms of the common cold. A careful 
analysis of Chalmers' review reveals serious shortcomings. For example, Chalmers did not 
consider the amount of vitamin C used in the studies and included in his meta-analysis was 
a study in which only 0.025–0.05 g/day of vitamin C was administered to the test subjects. 
For some studies Chalmers used values that are inconsistent with the original published results. 
Using data from the same studies, we calculated that vitamin C (1–6 g/day) decreased 
the duration of the cold episodes by 0.93 ± 0.22 (SE) days; the relative decrease in the episode 
duration was 21%. The current notion that vitamin C has no effect on the common cold seems 
to be based in large part on a faulty review written two decades ago.
Key teaching points:
* In 1975 Thomas Chalmers published a meta-analysis of studies that have 
examined the role of vitamin C supplementation on common cold morbidity.
* Chalmers' paper is often cited as proof that vitamin C has no value 
in treating the common cold.
* The present study shows that Chalmers' analysis is fraught 
with errors and misleading data from the original studies.
Dedicated to the memory of Professor Linus Pauling (1901-1994)
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INTRODUCTION
There exists a long-standing controversy concerning the possible efficacy of vitamin C 
in treating the common cold. The first reports indicating that vitamin C may be beneficial 
against the common cold were published in the 1930's and 40's [1-4]. The topic received 
wide publicity in the 1970's after Linus Pauling concluded from the published studies that
vitamin C, in doses ≥1 g/day, significantly decreases both the incidence and the severity 
of the common cold, and wrote a popular book discussing the topic [3,4]. Pauling also 
carried out a meta-analysis [5], one of the very first in medicine, of the published studies 
in which he demonstrated a significant decrease in total morbidity in the subjects 
ingesting vitamin C supplements (p < 0.00003). The claims of Pauling were not widely 
accepted within the medical community but they inspired a number of intervention 
studies to determine whether vitamin C does indeed have any actual effect. In fact, 
all 21 placebo-controlled studies published since 1970 which utilize ≥1 g/day of vitamin 
C have reported a decrease in the severity of symptoms or in the duration of the common 
cold episodes [6,7].
The general belief in conventional medical circles that vitamin C has no effect on 
the common cold [8-10] seems surprising since essentially all of the placebo-controlled 
studies carried out both before and after Pauling's conclusions have shown a beneficial 
effect [3-7]. We believe that the current conception that vitamin C does not affect the 
common cold can be traced largely to the review written by Chalmers in 1975 [11]. 
Chalmers carried out a meta-analysis of studies performed before 1975. From the results 
of seven studies, he calculated that the difference in the duration of episodes between 
the vitamin C and placebo groups was 0.11 ± 0.24 (SE) days, a difference considered 
by Chalmers to be "minor and insignificant", even though he noted that "in most 
studies the severity of symptoms was significantly worse in the patients who received 
the placebo." Based on his analysis, Chalmers stated "since there are no data on 
the long-term toxicity of ascorbic acid when given in doses of 1 g or more per day, 
it is concluded that the minor benefits of questionable validity are not worth 
the potential risk, no matter how small that might be [11]."
Chalmers' review has been cited twice as often as Pauling's meta-analysis (Table 1). 
Pauling's books have been extensively cited (Table 1), but this gives a highly misleading 
impression of their true scientific impact. In the current edition of the Recommended 
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Dietary Allowances (RDA), Pauling's meta-analysis is mentioned, but Chalmers' review 
is referred to as proof that Pauling's conclusions were incorrect [8]. In monographs on 
infectious diseases Pauling's books and meta-analysis are rarely mentioned; rather, 
Chalmers' review is referred to as evidence that vitamin C has no effect on the common 
cold [9,10]. Chalmers' conclusions [11] of the published studies vary from that of other 
reviewers [3-7]. The present work analyzes the reasons for this apparent discrepancy.
Table 1. Citations of Reviews Analyzing the Vitamin C-Common Cold Studies [12]
Years Chalmers'review [11]
Pauling's
meta-analysis [5]
Pauling's 
two books [3,4]
1970-75 -   7    75
1975-79 24 15 123
1980-84 18   6   69
1985-89 14   2   35
1990-92   5   1   15
Total citations: 61 31 317
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ANALYSIS OF CHALMERS' REVIEW
Shortcomings in Chalmers' Table II
The argument in Chalmers' review is based primarily on his table II, which contains studies 
that he referred to as "reasonably well controlled studies." Chalmers' table II is reproduced 
here (Table 2) in order to show the various shortcomings in his analysis and to compare 
different ways of summarizing the data in order to estimate the treatment effect. A summary 
of the same studies by the present authors is presented as Table 3. Several of the numerical 
values presented by Chalmers are dubious for various reasons and these are underlined 
in Table 2.
Table 2. Ascorbic Acid and the Common cold: 
Reasonably Well-Controlled Studies according to Chalmers [11]
Study [reference]
   Ascorbic acid         Placebo      Difference 
in duration
(days)
No. of
subjects
Mean
 duration
 (days)
No. of
subjects
Mean 
duration 
(days)
Anderson et al 1972 [13] 407 3.96 411 4.18   0.22
Anderson et al 1974 [14] 583 3.28 578 3.18 –0.10
Coulehan et al 1974 [15] 321 4.71 320 5.92   1.21
Wilson et al 1973 [16] 158 2.65 144 2.79   0.14
Karlowski et al 197  4   [17] 101 6.80   89 6.30   0.50 
Cowan et al 1942 [2] 233 1.10 194 1.60   0.50
Cowan et al 1942 [2] 227 1.70 120 1.00 –0.70
Mean ± SE: 0.1  1   ± 0.24
Ritzel 1961 [18] 139 1.35 140 1.95   0.60
Chalmers also listed the incidences of colds but they are left out to save space. 
Erroneous and misleading numerical values are indicated by yellow  and  underlining   
(see text and compare to Table 3).
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Table 3. Ascorbic Acid and the Common Cold: Results from the Original Publications
Study [reference]
Vitamin 
C
dose
(g/day)
   Ascorbic acid          Placebo       
Difference 
in days
Relative 
difference
(%)
Probability 
of difference
(2-tailed)No. of subjects
Mean 
duration
(days)
No. of 
subjects
Mean 
duration
(days)
Dose ≥1 g/day
Anderson et al 1972 [13,19] 1+3 407 3.96 a) 411 4.18 –0.22  –5
1.04 b) 1.32 –0.28 c) –21 c) p < .05
Charleston & Clegg 1972 [20,21] 1   47 3.5   43 4.2 –0.7 c) –17 c) p < .05
Anderson et al 1974 [14] 1–5 860 1.74 b) 285 e) 1.76 –0.02  –1
1–5 860 1.74 b) 293 f) 1.54 +0.20 +13
Coulehan et al 1974 [15] 1 190 g) 4.95 192 5.65 –0.70 c) –12 c) p < .01 h)
2 131 g) 4.44 128 6.29 –1.85 c) –29 c) p < .05 h)
Karlowski et al 1975 [17] 3 i)   87 6.59   46 7.14 –0.55  –8
3+3   57 5.92   46 7.14 –1.22 c) –17 c) p < .05 j)
Ritzel 1961 [5,18,22] 1 139 1.8 140 2.6 –0.8 c) –31 c) p < .05
Mean ± SE:  –0.93 ± 0.22 c) –21 ± 3 c)
p = 0.01 c p = 0.001 c) p < 0.000004 k)
Dose <1 g/day
Cowan et al 1942 [2] 0.2 208 l) 0.58 m) 155 0.73 –0.15 –21
Cowan et al 1942 [2]
0.025–0.0
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170 l) 0.71 m)   94 0.42 +0.29 +69
Wilson et al 1973 [16] 0.2   70 n) 2.62   58 3.10 –0.48 –15
Wilson et al 1973 [16] 0.2   88 o) 2.68   86 2.48 +0.20   +8
a) Duration of symptoms.
b) Days confined to house.
c) Mean ± standard error (SE) of the point estimates for studies marked with superscript c) ; 
the p-value was calculated from the same point estimates with the 2-tailed t-test.
d) Study groups #1, #2, and #3 combined, all with ≥ 1 g/day of vitamin C.
e) Placebo group #4.
f) Placebo group #6.
g) School children of upper classes received 2 g/day and of lower classes received 1 g/day.
h) Significance for the total decrease in days of morbidity.
i) Two 3 g/day groups are combined (cf. Table 4).
j) Calculated by these authors from Table 4 with the t-test; the significance of the difference 
was not calculated by Karlowski et al [17].
k) The probabilities of the studies marked with superscript c) have been combined with Fisher's method [23,24].
l) The number of subjects who completed the study; Chalmers gives the number of subjects who began the study.  
Two study groups are combined in the 0.025–0.05 g/day results.
m) Days lost from school per one episode; Chalmers gives the total number of days lost from school, i.e., over all episodes.
n) Schoolgirls.
o) Schoolboys.
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Table 4. Results from the Common Cold Study by Karlowski et al [17]
Group Tablets No. of 
Subjects
Vitamin C
during a cold
(g/day)
Duration 
(days; mean ± SE)
Difference
(%)Prophylactic Therapeutic
1 P P 46 0 7.14 ± 0.46
2 P C 43 3 6.46 ± 0.39 –10
3 C P 44 3 6.71 ± 0.53  –6
4 C C 57 6 5.92 ± 0.40 –17
Prophylactic tablets were given each day, i.e. also during the colds, 
and the therapeutic tablets were given for 5 days when the subject caught a cold. 
Tablets: P = placebo (lactose); C = vitamin C (ascorbic acid, 3 g/day). The data were taken from [11,17].
Chalmers' placebo group is indicated by yellow (cf. Table 2)
The data of the Karlowski study [17] are not correctly presented by Chalmers. Karlowski et al
used four study groups and only one of these was a true placebo group; three other groups 
received vitamin C (3–6 g/day) according to different protocols (Table 4). The true placebo 
group in the study by Karlowski et al contained 46 subjects and the mean duration of the 
common cold episodes was 7.14 days (Table 4). However, Chalmers states that the number 
of subjects in the placebo group was 89 and the mean duration was 6.3 days (Table 2). 
Apparently, Chalmers totaled the number of subjects in groups 1 and 2 (n = 89), when in fact, 
group 2 received 3 g/day of vitamin C for therapy and cannot be considered a placebo group. 
Furthermore, the average for groups 3 and 4 (i.e. not groups 1 and 2) is 6.3 days. During 
the common cold episode, groups 3 and 4 were administered 3–6 g/day of vitamin C, but 
Chalmers gives their average as the duration in the "placebo" group (Table 2). Chalmers states
that the number of subjects in the vitamin C group of Karlowski et al was 101 (Table 2) which
is the sum of the subjects in groups 3 and 4 (Table 4). For the duration of cold episodes 
in the vitamin C group, Chalmers gives the value 6.8 days (Table 2) which is the average 
for groups 1 and 2 (group 1 was the true placebo group). Thus, when pooling the results, 
Chalmers combined the placebo group with one of the vitamin groups (groups 1 and 2), 
and two vitamin groups receiving different doses (groups 3 and 4). Thereafter, Chalmers 
exchanged the duration of the cold episodes for the two pooled groups (Tables 2 and 4).
Regarding the first study by Anderson et al [13], Chalmers displays the duration of colds 
according to the presence of symptoms (5% decrease with vitamin C; Table 2). However, 
Anderson et al observed a much greater effect on the outcome parameter "days indoors" 
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(Table 3). This latter parameter apparently is more interesting for patients, since it is 
a measure of how much the common cold infections cause actual functional limitations. 
Accordingly, Chalmers' presentation of the duration of symptoms only, which did not reach 
statistical significance (Table 3), is misleading.
In case of the second study by Anderson et al [14], Chalmers gives the duration for a placebo 
group without indicating that there were actually two placebo groups in the study (Tables 2 
and 3). There were great differences in these two placebo groups, these being a 14% 
difference in "days indoors" (Table 3) and a 30% difference in the duration of symptoms [14]. 
Furthermore, when the subjects were asked at the start of the trial for their recollection of 
"usual days indoors" during a typical common cold episode, placebo group #4 gave the largest
value (2.57 days), and the other placebo group, #6, gave the smallest (1.97 days) among eight 
study groups, six of which were given vitamin C according to different protocols. The average
of "usual days indoors" for three groups with regular vitamin C intake (≥1 g/day) was 2.34 
days [14], which is 19% higher than the value for the placebo group #6. During the trial, the 
difference between the three vitamin C groups and the placebo group #6 was +13% (Table 3), 
which may suggest a small benefit when compared to the bias in the recollection. In any case, 
there seem to have been considerable biases in the allocation of subjects into the eight groups 
and this problem was discussed by the authors [14]. Chalmers gives just two values derived 
from the study (Table 2) with no comments on the complexity of the study which may give 
a misleading impression of the reliability of the values presented.
In some of the publications dealing with the effect of vitamin C on the common cold two 
independent studies are reported simultaneously. In the case of the Cowan et al publication 
[2], Chalmers correctly presents the two studies separately. However, Coulehan et al [15] 
examined independently the effect of 1 g and 2 g daily vitamin C dosages on clinical episodes
of illness, but Chalmers combines the two studies together (Tables 2 and 3). This gives more 
implicit emphasis to the two studies by Cowan et al. More importantly, when the estimate 
of the effect is calculated, the work of Cowan et al is thereby given a weighting factor of two, 
while the work of Coulehan et al gets a weighting of one.
Wilson et al also reported the results of two independent studies, one with boys and another 
with girls [16], and these too are presented as a single study by Chalmers (Tables 2 and 3). 
For girls, Wilson et al found a 15% decrease in the duration of episodes and a 45% decrease 
(p < 0.05) in the intensity of symptoms [16]. Vitamin C did not benefit boys (Table 3). In a 
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more recent study Miller et al also found that vitamin C decreased the duration and severity in
girls (p < 0.05) but not in boys [25]. In the latter study, the investigators observed that in boys 
given placebo, the vitamin C content of urine was increased during the study period, 
a phenomenon not observed in girls [25]. Thus, it is possible that the boys exchanged their 
tablets to some degree in the studies by Miller et al and Wilson et al. By combining the two 
studies of Wilson et al in his table II, Chalmers masked the marked benefit observed in girls, 
although Chalmers did remark in the text that in the studies by Wilson et al and by Coulehan 
et al, "the effects on symptoms seemed to be more striking in girls than in boys."
Chalmers states that the duration of episodes in the early study by Ritzel was 1.35 and 1.95 
days in the vitamin and placebo groups, respectively (Table 2). In the original article, Ritzel 
gives values of 1.8 and 2.6 days, respectively [18]. Chalmers gives no explanation for this 
discrepancy [11].
In a footnote to his table II Chalmers noted that in the studies by Cowan et al there had been 
"blinding of subjects only" and that "subjects were assigned to ascorbic acid or placebo 
group alternately" [11]. However, Chalmers collected poor quality studies in his table I 
specifically, with a title "neither randomized nor double blind", and it is not clear why 
he did not include the Cowan et al studies in that table. In contrast, Chalmers included the 
study by Charleston and Clegg [20], a single blind placebo-controlled study which found 
a significant benefit from the vitamin, in his table I. Technically the latter study is quite similar
to the studies by Cowan et al except that a much larger dose of the vitamin was used 
(1 g/day). Thus, Chalmers was not consistent in selecting the studies for his table II. 
We have included Charleston and Clegg's study in our Table 3.
In retrospect, it is also possible to ask whether Chalmers employed the most appropriate 
statistical methods for analyzing the data he had available to him. For example, he did not 
weight the individual means with the number of subjects to arrive at a mean difference 
in duration per individual. Also, unlike Pauling [5], Chalmers does not report or analyze 
the p-values found in the studies [11].
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Role of Vitamin C Intake in the Treatment and Control Groups
An important variable in vitamin C studies is the amount of the vitamin administered to the subjects
but this variable was not taken into account by Chalmers. In fact, Chalmers included the study 
by Cowan et al in which only 0.025–0.05 g/day of vitamin C was given to the test group (Tables 2 
and 3). If vitamin C does have biochemical effects resulting in the alleviation of common cold 
symptoms, a dose-response relationship would be apparent: very small dosages may be ineffective, 
whereas large dosages could produce moderate benefits. In addition, the subjects in the 0.025–0.05 
g/day group of Cowan et al received several other vitamins simultaneously (vitamins A and D, 
thiamine, riboflavin, nicotinic acid) in addition to the small dose of vitamin C [2], and therefore 
any observed differences cannot be attributed specifically to vitamin C. For these reasons one might
argue that this 0.025–0.05 g/day study should not have been included in Chalmers' analysis.
The optimum dose of vitamin C is not obvious [4,6,26]. Pauling selected studies for his 
meta-analysis in which more than 0.1 g/day of vitamin C was regularly used [5]. Furthermore, 
Pauling pointed out that the greatest benefit was observed in Ritzel's study in which the largest 
dose was used (1 g/day; [18]), and this led Pauling to propose 1 g/day or more for the prevention 
and treatment of the common cold [3-5]. A dose-response effect is also seen in the studies 
Chalmers cited. Studies using at least 1 g/day of vitamin C show quite a consistent benefit, 
whereas studies with smaller doses show less consistent results (Table 3). Furthermore, Coulehan et
al [15] and Karlowski et al [17] found a greater benefit in the study group given a larger dose 
of the vitamin (Table 3). Anderson et al compared the effect of 4 and 8 g/day of vitamin C when 
given, in several doses, only on the first day of illness [14]; the larger dose was consistently more 
beneficial when eight types of symptoms were measured. Thus, by including studies using small 
amounts of vitamin C (<1 g/day), Chalmers diluted the positive effects noted in studies using 
large amounts of vitamin C (≥1 g/day).
Furthermore, to test whether ≥1 g/day of vitamin C bestows benefits beyond those obtained on 
the RDA level of intake (0.06 g/day; [8]), the control group should not be allowed significant 
dietary intake of the vitamin. If the control group receives large amounts of vitamin C, a false 
negative result or a very small effect may result. A healthy diet containing large amounts of fruits 
and vegetables may provide more than 0.5 g/day of vitamin C, and in certain studies the control 
group apparently received large amounts of vitamin C in its diet [6,25]. Anderson et al [13] found 
that vitamin C supplementation was more beneficial to those who had a low intake of fruit juices 
compared to those with a high intake (a decrease of 48% and 22%, respectively, in total days 
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indoors due to the common cold). The subjects of the Karlowski study [17] were employees 
of the NIH and therefore their dietary intake of vitamin C may have been much higher than 
the average in the United States; this could explain the rather small benefit observed when 
considering the high doses tested (Table 3). Thus, the dietary intake of vitamin C is an important 
modifying factor in the studies but it was not considered by Chalmers.
Calculation of an Estimate for the Benefit of Vitamin C
When Chalmers summarized the results for the effect of vitamin C on the duration of episodes, 
he calculated the average number of days saved by vitamin C administration per episode (Table 2). 
However, depending on the definition of disease (i.e. the outcome parameter) and on several other 
factors, the duration of the episode may be short or long, there being a ten-fold variation in the 
duration in different control groups in Table 3. When absolute values (days) are used in calculating 
the estimate of the effect, a great weight is given to studies with long duration of episodes. 
However, if a 3-day cold is shortened by 1 day, and a 6-day cold by 2 days, it seems inappropriate 
to conclude that the latter effect is twice the former. Instead, one may consider that both decreases 
are 33%. Thus, the absolute difference (days) used by Chalmers may not be the best parameter 
when comparing the various common cold studies. Calculation of the relative effect may instead 
be a better means of comparing equivocal outcome parameters.
Furthermore, when Chalmers calculated the average effect, he segregated Ritzel's study from 
the other studies, even though he listed it in his table II. Chalmers argued that the study was not 
reliable since it lasted for a short period (1 week). However, a short duration may be compensated 
with a fairly large number of subjects and a fairly high incidence of cold episodes; both of which 
occurred in Ritzel's study which was carried out at a ski school in the Swiss mountains [18,22]. 
If Chalmers included the study by Ritzel in his calculation, calculated the differences in the study 
by Karlowski et al correctly, omitted the low-dosage studies (<1 g/day), and chose "days indoors" 
as the most relevant outcome parameter from Anderson's first study, vitamin C would have 
appeared much more effective.
In Table 3 we briefly present our analysis of the studies reviewed by Chalmers. We calculated 
the relative difference in the duration of colds to normalize the episode duration among the various 
studies. If the second study by Anderson et al [14] is excluded because of the technical problems 
discussed above, the mean decrease is 21% (median 19%). There are 13 studies not discussed 
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by Chalmers in which a regular dose of ≥1 g/day has been used [6,7]; they have mostly been 
published after Chalmers' review. In these studies, the mean decrease in duration or severity 
of symptoms was 26% (median 22% [6,7]); therefore, Chalmers could have made a good estimate 
of the average benefit from vitamin C supplementation (≥l g/day). However, as noted above, there 
is dose-dependency in the effect. The average benefit in all studies to date with 1 g/day has been 
19% (median 13%) and in studies with 2–4 g/day it has been 29% (median 29%) [6,7].
Even though we consider the relative difference is a more meaningful parameter than the absolute 
difference (days), we also calculated the average for the absolute differences to allow explicit 
comparison of our Table 3 with Chalmers' table II. Vitamin C (1–6 g/day) would save 0.93 ± 0.22 
(SE) days of illness per episode (Table 3). The latter value contrasts sharply with the average 
calculated by Chalmers, according to whom the difference between the vitamin C (0.025–6 g/day) 
and control groups is only 0.11 ± 0.24 (SE) days of illness per episode. Thus, from the studies that 
were known to Chalmers, an eight-fold higher estimate of the decrease in the duration of episode 
could have been obtained for vitamin C dosages suggested by Pauling [3-5]. In contrast to 
Chalmers' estimate, our estimate, 0.93 days saved per episode, significantly differs from zero 
(p = 0.01). It is noteworthy that the p-value for the estimate of the relative decrease in duration, 
–21%, is even lower (p = 0.001), apparently reflecting the benefits of the normalization procedure. 
Nevertheless, these p-values are conservative estimates of all the evidence. The individual p-values 
can be combined, for example, using Fisher's method [23,24], yielding a combined p < 0.000004.
The variability in the definition of the outcome parameter makes us cautious regarding the 
significance of the exact estimate of the benefit. However, the magnitude of the average decrease 
(21%) by 1–6 g/day of the vitamin (or 29% by 2–4 g/day; [6,7]) seems to be potentially important 
considering that the common cold is the most frequent cause for absenteeism from work and school
and one of the most common causes of visiting the physician [9,10]. Vitamin C is a very cheap 
nutrient, with no known harmful effects in the general population from 1 g/day even with long-term
usage [27,28]. For example, none of the common cold intervention studies using ≥1 g/day of 
the vitamin, which have contained over 6000 subjects in total, have reported any significant harmful
effects [6,7,13-20]. Research has indicated that our ancestors ate 0.4–2 g/day of vitamin C [29,30], 
and the gorilla, a close biological relative of humans, eats about 4 g/day of vitamin C [31]. 
Therefore, these doses are not unfamiliar to human physiology (i.e. not pharmacological) even 
though they are much larger than the RDA (0.06 g/day; [8]).
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Placebo Effect is not a Valid Explanation of the Differences
In his review, Chalmers suggested that the benefit due to vitamin C reported in several studies 
could result from the placebo effect [11]. He based this suggestion on the study by Karlowski et 
al [17], in which the subjects who could correctly identify vitamin C reported greater benefit 
from the vitamin than those who could not identify it. In Karlowski's study, the placebo consisted
of lactose, which can easily be distinguished from ascorbic acid by taste. However, in a large 
number of studies it has been explicitly reported that the placebo tablets were indistinguishable 
from the vitamin C tablets [2,6,7,13-15,20,22]. The tablets have often contained citric acid 
[13-15,20]. It appears unlikely that the placebo effect would explain the benefits observed when 
valid placebo tablets are used.
One may question whether Chalmers' suggestion of the role of the placebo effect is valid even 
in the case of the Karlowski study. After the study, Karlowski et al found by questionnaire that 
many of the subjects guessed correctly whether they were being given lactose or ascorbic acid 
[17]. The investigators reanalyzed their results by forming two groups from the subjects: those 
who correctly guessed their treatment, and those that did not try to guess their treatment. There 
were large differences in the duration of episodes between the vitamin and placebo groups 
among subjects who guessed their treatment correctly, but no marked differences in subjects who
did not make the guess [17]. This led Chalmers to conclude that the observed differences were 
due to the placebo effect [11].
One should be cautious when dividing subjects into subgroups according to factors that may be 
associated with a possible real benefit and guessing the treatment is one of such factors. If 
vitamin C does produce a significant benefit certain people may identify the vitamin from its 
physiological effects. For example, Asfora initiated a double-blind study to test the effects of 
6 g/day of vitamin C on the common cold, but subjects receiving the vitamin could be identified 
by their clinical progress [32]. Thus, it is possible that in Karlowski's study, mild common cold 
symptoms led some subjects to correctly infer that they received vitamin C, and severe 
symptoms led to the inference that placebo was administered; whereas symptoms of medium 
severity led people not to make any guess of the treatment. In any case, the validity of the 
placebo should be examined before the study [13-15] rather than after its completion, as was 
the case in this poorly conducted study [17].
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CONCLUSIONS
Chalmers' review of vitamin C and the common cold has been a cornerstone for the belief that the 
vitamin has no significant effects in reducing the severity of the common cold. The review has been 
used in several monographs as a basis for the conclusion that vitamin C is worthless for the treatment 
of the common cold [8-10]. We have shown that Chalmers' review contains serious and numerous 
errors. Therefore, the widely-accepted notion that vitamin C does not have any significant effect on 
the common cold is largely based on an unreliable review. After Chalmers' review was published, 
a large number of placebo-controlled double-blind studies have been carried out. Their results 
consistently and persuasively support the conclusion that vitamin C supplementation alleviates 
the symptoms of the common cold [6,7,33]. Moreover, the benefit due to vitamin C can now be 
rationalized physiologically. Vitamin C may protect against the reactive oxygen species that are 
produced, e.g. by phagocytes during a viral infection [6,34-37]. Also, vitamin C may enhance the 
proliferative responses of T-lymphocytes [37-46], and increase the production of interferon [47-51].
In this paper we show that even with the studies that were available to Chalmers, a more reasonable 
selection of the studies, corrections in his abstractions of the published results, and appropriate analysis
would have indicated that vitamin C significantly decreases the duration of episodes of the common 
cold, a conclusion consistent with the studies carried out subsequent to the publication of Chalmers' 
review. Furthermore, in the period since the publication of Chalmers' review, the safety to the general 
population of long-term ingestion of large vitamin C doses has been established firmly [27,28]. Still, 
diarrhea and other gastrointestinal disturbances are sometimes associated with large doses (≥4 g/day) 
in healthy people [52]. However, people with the common cold infection can often ingest over 30 
g/day of vitamin C without getting diarrhea [52], apparently due to changes in vitamin C metabolism 
[6,53]. Finally, there is much evidence suggesting that large therapeutic vitamin C doses which start 
early in the course of the common cold episode significantly decrease the severity of symptoms 
[1,6,17,32,33,52,54-57], but the evidence showing the benefit of regular intake is much stronger 
as nearly all of the trials have studied the effects of regular intake.
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